Clinical Trial

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

Name: A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies — clinical trial record (NCT06274515)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: REMERGE

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.

Trial Details

NCT Number	NCT06274515
Lead Sponsor	Hoffmann-La Roche
Conditions	Breast Cancer
Enrollment	320 participants
Start Date	2024-04-02
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-06